Piperacillin/tazobactam versus carbapenems for 30-day mortality in patients with ESBL-producing Enterobacterales bloodstream infections: a retrospective, multicenter, non-inferiority, cohort study
Our findings indicate that piperacillin/tazobactam is non-inferior to carbapenems for treating extended-spectrum beta-lactamase-producing Enterobacterales bloodstream infections, with an acceptable 5% increase in 30-day mortality. We suggest that piperacillin/tazobactam should be used more frequently to decrease antimicrobial resistance.
Authors
- Johan Tham (ORCID: https://orcid.org/0000-0002-6994-1672)
- Lisa Mellhammar (ORCID: https://orcid.org/0000-0002-7623-0342)
- Kristian Riesbeck (ORCID: https://orcid.org/0000-0001-6274-6965)
- Torgny Sunnerhagen (ORCID: https://orcid.org/0000-0002-9240-2378)
- Thomas Sahlström Månsson (ORCID: https://orcid.org/0000-0003-4696-4588)
- Alice Askemyr (ORCID: https://orcid.org/0009-0002-9137-0877)
Institutions
- Ericsson (Sweden) (SE)
- Lund University (SE)
- Kristianstad University (SE)
- Sahlgrenska University Hospital (SE)
- Infection Prevention Society (GB)
- Skåne University Hospital (SE)
Publication Details
- Journal
- Infection
- Published
- 2025-04-16
- DOI
- https://doi.org/10.1007/s15010-025-02496-x
- Citations
- 5
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 2.96
Funders
- Lunds Universitet